Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer. - Wikidata - awgldk - TriplyDB

Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer.

Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer.

http://www.wikidata.org/entity/Q33658526

about

Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity Pharmacodynamic modelling of biomarker data in oncology.Neoadjuvant chemotherapy with gemcitabine for pancreatic cancer increases in situ expression of the apoptosis marker M30 and stem cell marker CD44.Advances in biomarker research for pancreatic cancer.Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer.Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma Circulating Levels of M30 and M65 Molecules in Transitional Cell Carcinoma of the Bladder and Their Relation to Tumor Progression.Pancreatic cancer biomarkers and their implication in cancer diagnosis and epidemiology.Early onset pancreatic cancer: a controlled trial.Utilization of cytokeratin-based biomarkers for pharmacodynamic studies.The M30 assay does not detect apoptosis in epithelial-derived cancer cells expressing low levels of cytokeratin 18.Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma.M30/M65 ratio predicts the outcome of paclitaxel chemotherapy for NSCLC.Effect of chymotrypsin C and related proteins on pancreatic cancer cell migration.

P2860

Q34024427-0EE2609F-1B4B-412B-A06C-7D1556A33A24 Q34241935-59FC6832-4D91-4CE2-81EF-18A4FC7F422C Q36084344-45193C5F-397A-43E9-9C04-AB1B521A6C0D Q36126609-74D87976-8A39-416E-9AC2-24BB60B39228 Q36385291-C35FE3BF-0353-4E26-9D77-A9C2CFCE8FEB Q36661995-DCF6B2B8-6FDC-4E3F-9362-1BC959B7E06E Q37111059-3B1C95FE-0EDF-4920-930E-BE9BF9370487 Q37342746-0ECBA9D8-B03B-4718-9DD0-3F69CA8C12F6 Q37647143-856953D3-25D8-440C-91B9-6F2AE4C9376C Q37724878-7C27F07D-CA9A-4A05-9330-756A36237EC8 Q38890416-470754A1-2A85-489B-9AC6-1E5AC99A118A Q50893230-43C58D93-4D8A-40FC-9B6A-99B192953D4A Q51226881-2EAA0532-DDA0-4B2E-AE40-0EE145ABA166 Q51874385-5C4E3D39-CD20-4543-9DA7-9FDA29387C5B

P2860

Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer.

http://www.wikidata.org/entity/Q33658526

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer.

@ast

Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer.

@en

type

label

Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer.

@ast

Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer.

@en

prefLabel

Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer.

@ast

Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer.

@en

P1433

Q33658526-25981F15-34DF-48CC-86A4-9203E597A406

P1476

Q33658526-BD89D841-EE02-45F3-84BB-B4772BDFD4AD

P2093

Q33658526-0504F90A-AE13-464B-92E6-54AAC747D8F0

Q33658526-1247D55B-30E4-4838-883B-4EDB347BBE23

Q33658526-15D50648-BDFF-4F08-A2BC-25CDEAED8554

Q33658526-9BA8C595-8826-42C8-BAAC-00E0225C3C3E

Q33658526-A9EFFDCC-464C-400D-B23C-F44BE68FF2DB

Q33658526-AF0B2E2A-53E3-4626-B29C-3A2131BCFA61

Q33658526-C9A28C0B-CF63-446E-B8D2-D79648C9474F

P2860

Q33658526-041CF49E-51E3-4A17-8D04-F2CDBAE09588

Q33658526-0499C42F-CB7C-47CA-A9EF-17478772952F

Q33658526-17F42877-B678-4BB1-8F04-05615FCB4846

Q33658526-352E14B3-CD73-445A-8E96-433E4F879AD4

Q33658526-35BFE426-D135-4924-AA33-A513110989A1

Q33658526-430A7AE1-3EA4-4632-AD5C-2FB5D384C392

Q33658526-588276BF-F04D-4D38-A8A6-72824D20D016

Q33658526-67A35B4D-9C8E-4740-A978-FBA8AE38ABEC

Q33658526-6A486AD1-C1B3-4E7E-B420-8BE710CF877B

Q33658526-6A5C0140-5B47-4BE2-8A78-C02956EA3E76

P2888

Q33658526-C2044708-3664-4E4B-ABA7-E212084A6A36

P304

Q33658526-6CF7DBA4-D6E7-436E-94A2-8272BB942E7A

P31

Q33658526-09A334F0-30AB-44B7-BFDB-CCE02735F8A2

P356

Q33658526-ED1C3985-2FB9-4E98-AC55-34E387E5741A

P407

Q33658526-220F32BF-449D-4990-9DD3-294C79BBB4BF

P433

Q33658526-95DECF68-949D-4BAB-A8F7-0176CC09CF9A

P478

Q33658526-C4BDBFD3-A22F-455B-A13D-D487F450C25D

P50

Q33658526-79B78414-0B2B-4975-B773-5976C0B2C81D

Q33658526-AC7400CB-343C-4F25-86A2-40DA64B36291

P577

Q33658526-E81A3C5C-036F-4DC7-B51A-8983B4AE89B2

P5875

Q33658526-68D65F41-97AC-4D9B-BAD8-625B25906950

P6179

Q33658526-CC82B778-70C4-4961-ACDF-878634E20662

P698

Q33658526-3AABC20B-2399-48A0-8245-B5B3206371EA

P921

Q33658526-2FA62786-3F7B-4D47-9A76-CB03F6C3E29D

P932

Q33658526-E086F858-162D-4608-9DFE-77E774B3170F

P356

P1433

British Journal of Cancer

P1476

Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer

@en

P2093

E Garner

http://www.w3.org/2001/XMLSchema#string

F Campbell

http://www.w3.org/2001/XMLSchema#string

P Ghaneh

http://www.w3.org/2001/XMLSchema#string

R A Smith

http://www.w3.org/2001/XMLSchema#string

S St George-Smith

http://www.w3.org/2001/XMLSchema#string

T Ward

http://www.w3.org/2001/XMLSchema#string

W Greenhalf

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer

Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy

Intermediate filaments: structure, dynamics, function, and disease

Confounding effect of obstructive jaundice in the interpretation of proteomic plasma profiling data for pancreatic cancer.

Circulating cell death products predict clinical outcome of colorectal cancer patients

Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis.

Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18.

Current standards of surgery for pancreatic cancer.

Biomarker method validation in anticancer drug development

Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer.

P2888

P304

577-582

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605494

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

John P Neoptolemos

P577

2010-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40850772

http://www.w3.org/2001/XMLSchema#string

P6179

1049468358

http://www.w3.org/2001/XMLSchema#string

P698

20051949

http://www.w3.org/2001/XMLSchema#string

P921

P932

2822934

http://www.w3.org/2001/XMLSchema#string